Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Organogenesis Holdings Inc (NASDAQ: ORGO) was $2.39 for the day, down -4.02% from the previous closing price of $2.49. In other words, the price has decreased by -$4.02 from its previous closing price. On the day, 1.24 million shares were traded. ORGO stock price reached its highest trading level at $2.52 during the session, while it also had its lowest trading level at $2.385.
Ratios:
Our analysis of ORGO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 48.37. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 07, 2024, initiated with a Overweight rating and assigned the stock a target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.
BTIG Research Upgraded its Neutral to Buy on May 24, 2023, while the target price for the stock was maintained at $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 10 ’24 when ERANI ALBERT sold 17,972 shares for $4.28 per share. The transaction valued at 76,875 led to the insider holds 59,007,134 shares of the business.
ERANI ALBERT sold 17,972 shares of ORGO for $76,875 on Jan 10 ’24. The 10% Owner now owns 59,007,134 shares after completing the transaction at $4.28 per share. On Jan 09 ’24, another insider, ERANI ALBERT, who serves as the 10% Owner of the company, sold 197,921 shares for $4.37 each. As a result, the insider received 863,985 and left with 59,025,106 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 330104448 and an Enterprise Value of 333228992. As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 65.12, and their Forward P/E ratio for the next fiscal year is 28.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 27.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 0.769 whereas that against EBITDA is 10.516.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $4.70, while it has fallen to a 52-week low of $1.93. The 50-Day Moving Average of the stock is -16.34%, while the 200-Day Moving Average is calculated to be -21.49%.
Shares Statistics:
ORGO traded an average of 892.05K shares per day over the past three months and 1446690 shares per day over the past ten days. A total of 131.32M shares are outstanding, with a floating share count of 77.59M. Insiders hold about 41.47% of the company’s shares, while institutions hold 44.63% stake in the company. Shares short for ORGO as of 1713139200 were 8320840 with a Short Ratio of 9.33, compared to 1710460800 on 8010519. Therefore, it implies a Short% of Shares Outstanding of 8320840 and a Short% of Float of 27.32.
